

Do meta-analyses of adverse events have adverse effects?

PICOT, Peto and Pitot

Stephen Evans

Improving health worldwide

www.lshtm.ac.uk

LONDON
SCHOOL of
HYGIENE
& TROPICAL
MEDICINE





Outline

- What is an adverse effect of an AE M-A?
- Where can it go wrong?
- PICOT
- 2 examples
 - with Peto
- Pitot

What is an adverse effect of an AE M-A?



- Getting a wrong or misleading answer
 - Claiming to find an adverse effect wrongly (Type I)
 - Failing to find a real adverse effect (Type II)
- Misleading communication of a correct answer
- Failing to provide the whole picture

Where can it go wrong?



- At all stages of the meta-analysis:
 - Setting the question
 - Design - protocol
 - Execution
 - Analysis
 - Report writing
 - Publication
 - Communication

PICOT



- *Picot stitch in crochet;*
- *Italian grape Nebbiolo in DOCG Barolo wines*
- **Patient populations - Do they match those treated**
- **Intervention**
- **Comparison**
- **Outcome**
- **Time**



Example-1

Olanow C, et al. Effect of selegiline on mortality in patients with Parkinson's disease: a meta-analysis. *Neurology*. 1998;51:825–830.

HR for mortality 1.02 (95% CI 0.44 to 2.37; $p = 0.96$)

14 deaths

Problem: [**P**]Used young patients & Excluded non-double blind trials: Concluded no increase – wrong?

By far the largest trial was open, used older patients :

HR 1.57 (95% CI 1.07 to 2.30)

76 deaths



Example 2: Nissen

- 42 trials, “randomized comparator group, a similar duration of treatment in all groups, and more than 24 weeks of drug exposure” (and >0 events)
- Compared MIs & CV deaths
 - OR for MI 1.43
 - (95% CI 1.03 to 1.98; P = 0.03)
 - OR for CV death 1.64
 - (0.98 to 2.74; P = 0.06)



Some Comments on Nissen M-A


- Not clear why MI chosen & CV death
- ?All CV events & all cause mortality? [O]
- Pooled comparison groups (ADOPT)
- Statistical method used is Peto
 - Fixed effects, good for rare events, see
 - Bradburn et al. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med 2007;26:53-77
 - but slightly biased with unequal randomisation



Nissen M-A

- No forest plots? No protocol? [**Design, Ex**]
- No discussion of absolute event rates
- Highest risk when RSG+insulin v insulin
 - OR 2.78 (0.58–13.3)
 - RSG contraindicated with insulin in EU
 - if these excluded all “significance” disappears
- **Peto** type methods gives a significant result for MI, others do not
- 2 large trials have 42 RSG MI & 14 RSG deaths from CVD
- Small trials have 44 RSG MI, 25 RSG deaths from CVD
 - 21 trials with 1v 0 events for MI

forest plot MI




MI - Small trials only



Study —

4 9653 /011
4 9653 /094
4 9653 /211
AVM1002 64
BRL4 9653/3 34
4 9653 /015
4 9653 /079
4 9653 /082
4 9653 /085
4 9653 /134
4 9653 /135
4 9653 /136
4 9653 /145
4 9653 /162
4 9653 /330
4 9653 /137
SB-7 12753/ 002
4 9653 /132
AV A10 0193
4 9653 /020
4 9653 /024
4 9653 /093
1 0068 4
4 9653 /143
4 9653 /284
7 1275 3/008
BRL4 9653C/1 85
BRL4 9653/3 47
4 9653 /080
4 9653 /097
4 9653 /125
4 9653 /127
4 9653 /128
4 9653 /147
SB-7 12753/ 003
SB-7 12753/ 007
4 9653 /095
4 9653 /331
4 9653 /234
SB-7 12753/ 009
O overall (95% CI)





Weights for **A**DOPT, **D**REAM, **O**thers in **M-A**


Odds Ratios MI

- (Peto) A 41 D 17 O 42
- (RE) A 41 D 14 O 45

Risk Differences MI

- (M-H) A 15 D 21 O 64
- (RE) A 4 D 20 O 76

MIs in trials with only 1 event





Comments

- Reliability of data from many small trials with zero or 1 event per arm is dependent on very good reporting
- *If M-A result very sensitive to the method used- be careful, even with Peto method- weights for many small trials can be equivalent to large trial*
- No benefit on MI for RSG, & possible harm, absolute rate uncertain (Singh JAMA Sept 2007)
- Need to see how hazard changes over time [T]
 - M-A for all surgery would show hazard of operations
- No benefit or harm on all-cause deaths

Pitot



- Pitot- 18th century French engineer.
- A pitot tube measures fluid flow – notably airspeed in aircraft.
- Can be used for “hot air”
- Media publicity around “scare” meta-analyses is often “**hot air**”

